Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

937 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Saida Y, Watanabe S, Tanaka T, Baba J, Sato K, Shoji S, Igarashi N, Kondo R, Okajima M, Koshio J, Ichikawa K, Nozaki K, Ishikawa D, Koya T, Miura S, Tanaka J, Kagamu H, Yoshizawa H, Nakata K, Narita I. Saida Y, et al. Among authors: shoji s. J Immunol. 2015 Jul 15;195(2):726-35. doi: 10.4049/jimmunol.1401468. Epub 2015 Jun 3. J Immunol. 2015. PMID: 26041539
Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.
Tanaka T, Watanabe S, Takahashi M, Sato K, Saida Y, Baba J, Arita M, Sato M, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Aoki N, Ohshima Y, Sakagami T, Abe T, Moro H, Koya T, Tanaka J, Kagamu H, Yoshizawa H, Kikuchi T. Tanaka T, et al. Among authors: shoji s. PLoS One. 2017 Aug 30;12(8):e0183976. doi: 10.1371/journal.pone.0183976. eCollection 2017. PLoS One. 2017. PMID: 28854279 Free PMC article.
PD-1 blockade therapy augments the antitumor effects of lymphodepletion and adoptive T cell transfer.
Takahashi M, Watanabe S, Suzuki R, Arita M, Sato K, Sato M, Sekiya Y, Abe Y, Fujisaki T, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Saida Y, Hokari S, Aoki N, Hayashi M, Ohshima Y, Koya T, Kikuchi T. Takahashi M, et al. Among authors: shoji s. Cancer Immunol Immunother. 2022 Jun;71(6):1357-1369. doi: 10.1007/s00262-021-03078-0. Epub 2021 Oct 17. Cancer Immunol Immunother. 2022. PMID: 34657194 Free PMC article.
Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity.
Arita M, Watanabe S, Aoki N, Kuwahara S, Suzuki R, Goto S, Abe Y, Takahashi M, Sato M, Hokari S, Ohtsubo A, Shoji S, Nozaki K, Ichikawa K, Kondo R, Hayashi M, Ohshima Y, Kabasawa H, Hosojima M, Koya T, Saito A, Kikuchi T. Arita M, et al. Among authors: shoji s. Sci Rep. 2021 Jan 12;11(1):750. doi: 10.1038/s41598-020-80853-6. Sci Rep. 2021. PMID: 33437029 Free PMC article.
Observational study of rebiopsy in EGFR-TKI-resistant patients with EGFR mutation-positive advanced NSCLC.
Koyama K, Miura S, Watanabe S, Shoji S, Koshio J, Hayashi Y, Ishikawa D, Sato K, Miyabayashi T, Okajima M, Ota T, Tanaka T, Matsumoto N, Kuriyama H, Abe T, Nozaki K, Ichikawa K, Kondo R, Tanaka H, Kikuchi T. Koyama K, et al. Among authors: shoji s. Sci Rep. 2022 Apr 16;12(1):6367. doi: 10.1038/s41598-022-10288-8. Sci Rep. 2022. PMID: 35430596 Free PMC article.
Phase II study of nanoparticle albumin-bound paclitaxel monotherapy for relapsed non-small cell lung cancer with patient-reported outcomes (NLCTG1302).
Shoji S, Miura S, Watanabe S, Ohtsubo A, Nozaki K, Saida Y, Ichikawa K, Kondo R, Tanaka T, Koyama K, Tanaka H, Okajima M, Abe T, Ota T, Ishida T, Makino M, Iwashima A, Sato K, Matsumoto N, Yoshizawa H, Kikuchi T. Shoji S, et al. Transl Lung Cancer Res. 2022 Jul;11(7):1359-1368. doi: 10.21037/tlcr-22-89. Transl Lung Cancer Res. 2022. PMID: 35958345 Free PMC article.
937 results